Building a safer medication management program for complex patients
Patients living with several chronic conditions often move between general practices, community pharmacies, hospitals and specialist clinics. Each service may have a legitimate reason for prescribing, yet the combined regimen can become difficult to understand, expensive to maintain and vulnerable to duplication, interactions or missed doses. A structured medication management program gives the care team a shared method for identifying risk and supporting the person who takes the medicines every day.
In Australia, this work needs to fit the realities of the Pharmaceutical Benefits Scheme, electronic prescriptions, My Health Record, residential aged care and variable access to healthcare outside major cities. The most effective program is practical rather than paperwork-heavy. It should clarify who is responsible for each task, include the patient’s priorities and make medication information useful at home, in the pharmacy and during transitions between services.
Start with a complete and reliable medicines picture
The first step is medicines reconciliation. Collect every prescription medicine, over-the-counter product, complementary medicine, inhaler, cream, eye drop and injectable treatment. Include medicines used occasionally, such as anti-inflammatory products, sleeping tablets and laxatives. Ask the patient to bring actual containers or photographs of labels rather than relying solely on memory or an outdated medication list.
Compare the patient’s account with dispensing records, hospital discharge documents, specialist letters and the list available through My Health Record when appropriate. A discrepancy is not automatically an error. The patient may have stopped a medicine because of dizziness, used a lower dose because of cost or continued a product that a prescriber assumed had been discontinued. Each difference needs clarification, documentation and communication with the relevant clinician.
A pharmacist-led interview should explore how medicines are taken in real life. Ask about work, meals, fasting, sleep, transport, dexterity, eyesight, memory and the person’s confidence with health information. A patient in regional Queensland may have limited access to a specialist or pathology service, while someone in inner Melbourne may have several providers but still struggle to coordinate them. The program must account for both kinds of complexity.
The assessment should also cover allergies, previous adverse reactions, renal and hepatic function, falls, cognition, alcohol use and pregnancy potential where relevant. Oral health deserves attention because dry mouth, dental decay, oral candidiasis and difficulty swallowing can affect adherence and quality of life. A practical oral health resource can support counselling when medicines or disease are contributing to mouth symptoms.
Agree on priorities, outcomes and responsibilities
A medication review should begin with the patient’s goals, not just a list of pharmacological problems. One person may want fewer episodes of hypoglycaemia so they can continue driving. Another may prioritise pain control, better sleep, fewer tablets or avoiding another hospital admission. Goals create a basis for deciding which medicines provide meaningful benefit and which burdens are acceptable.
Rank medication-related risks according to potential harm and urgency. High-priority issues may include an anticoagulant combined with frequent non-steroidal anti-inflammatory use, insulin administration errors, duplicate opioid therapy, untreated adverse effects, dangerously low blood pressure or a medicine that has accumulated because of reduced kidney function. Lower-priority issues can be scheduled for a later review rather than overwhelming the patient with simultaneous changes.
Every action should have an owner and a due date. The GP may assess diagnosis and deprescribing options, the pharmacist may reconcile products and provide adherence support, and a nurse may monitor symptoms, measurements or injection technique. Specialists should receive clear questions rather than a general request to “review medications”. The patient and carer should know whom to contact when a dose is missed or a new symptom appears.
A written care plan can include the medicine name, purpose, dose, timing, key precautions, monitoring requirements and the person responsible for follow-up. Use plain language and distinguish temporary treatments from long-term therapy. When a medicine changes, record the reason and the stop date for discontinued products. This reduces the risk that an old instruction will be copied into the next prescription or hospital transfer.
Design monitoring that fits everyday care
Monitoring should be proportionate to risk. A patient taking an angiotensin-converting enzyme inhibitor may need blood pressure, renal function and potassium checks, while someone using warfarin requires a clear anticoagulation plan and communication of dose changes. People prescribed medicines with sedative effects may need falls screening, driving advice and review of daytime alertness. The schedule should specify what is measured, the target or warning sign, and what happens when results are outside the agreed range.
| Medication management area | Practical action | Follow-up measure |
|---|---|---|
| Adherence and administration | Simplify timing, demonstrate devices and assess missed doses without blame | Patient can explain and demonstrate the regimen |
| Safety and interactions | Check allergies, renal function, duplicate therapy and high-risk combinations | Documented resolution or escalation of each concern |
| Effectiveness | Link each medicine to a symptom, clinical target or prevention goal | Relevant observations, pathology or patient-reported outcome |
| Adverse effects | Discuss expected effects and red flags in plain language | Fewer troublesome symptoms or timely clinical review |
| Transitions of care | Reconcile medicines after admission, discharge or specialist review | Updated list shared with the patient and care team |
| Adherence barriers | Address cost, transport, packaging, health literacy and routines | Fewer missed doses and improved confidence |
Choose tools that reduce effort rather than creating a second job. Dose administration aids can help some people, but they do not solve an unclear regimen or poor understanding. A medicines list on the refrigerator, a phone reminder, large-print instructions or a carer-supported routine may be more effective for another patient. In Aboriginal and Torres Strait Islander communities, culturally safe communication and locally trusted health workers can make the plan more acceptable and easier to sustain.
Follow-up should be scheduled around clinical risk. A recent discharge, new anticoagulant, opioid, insulin or antipsychotic may justify early contact within days. Stable therapy may need review at a longer interval, with an earlier appointment if symptoms or circumstances change. The program should include triggers for unscheduled review, including falls, confusion, repeated hypoglycaemia, emergency presentations, abrupt weight change or difficulty obtaining medicines.
Improve communication across the care team
Medication safety often fails at handover points. When a patient leaves hospital, the community pharmacy and GP need an accurate list showing what started, stopped, changed or should be used only for a limited period. Verbal communication can be valuable for urgent issues, but written confirmation prevents details being lost. Ask the patient to repeat the plan in their own words so misunderstandings are identified immediately.
Community pharmacists are well placed to notice early warning signs because they see refill patterns, questions about side effects and changes in presentation. Pharmacists can also help patients prepare for a GP appointment by identifying unanswered questions and checking whether a new medicine is being taken as intended. Where pharmacist prescribing or medicine administration services are available within local rules, the scope of the service should still be explicit and coordinated with the broader care plan.
Mental health deserves the same level of coordination as physical illness. Depression, anxiety, substance dependence and cognitive impairment can affect motivation, memory and safe medicine use. Pharmacists who want to strengthen their response can review guidance on the pharmacist mental health role, especially when a routine medicines conversation reveals distress or suicide risk.
Privacy and consent should be built into information sharing. Confirm which family members or carers may receive updates, use secure communication channels and document significant discussions. In small communities, discretion matters because patients may know pharmacy staff personally. A respectful explanation of why information is being shared can preserve trust while allowing clinicians to act safely.
Support deprescribing and sustained self-management
Medication optimisation includes considering whether a medicine is still needed, effective or aligned with the patient’s current goals. Deprescribing should be planned, monitored and agreed with the prescriber and patient. Some medicines require gradual dose reduction, and stopping several treatments at once can make it difficult to identify withdrawal effects or symptom recurrence. Explain the reason for each proposed change and provide a plan for what to do if problems occur.
Review medicines that commonly create cumulative harm in older adults or people with multiple conditions, including sedatives, anticholinergic medicines, long-term corticosteroids, opioids and medicines that increase bleeding or falls risk. This does not mean removing treatment simply because a patient is older. It means balancing benefit, time to benefit, treatment burden, life expectancy, function and the person’s preferences.
Adherence support should avoid moral judgement. Missed doses may reflect cost, confusing instructions, unpleasant effects, cultural beliefs, low mood, unstable housing or competing demands. PBS co-payments can still influence choices, particularly when several family members need medicines. Discuss generic or lower-cost alternatives with the prescriber where clinically suitable, and consider staged supply or dose administration support when it improves safety without reducing independence.
Antidepressant therapy illustrates why ongoing education matters. Formulations, release mechanisms, switching approaches and adverse-effect profiles can differ, so pharmacists should use current evidence and product information; a focused guide to antidepressant formulations can support that review. Patients should know how long benefit may take, which effects require urgent attention and why suddenly stopping treatment can be unsafe.
Measure results and keep the program usable
A medication management program should demonstrate value through outcomes that matter to patients and clinicians. Possible measures include medication discrepancies resolved, adverse drug events, hospital readmissions, falls, symptom scores, blood pressure control, glycaemic outcomes, adherence confidence and completion of follow-up reviews. Track a small number of meaningful indicators rather than collecting data that no one uses.
Review the program after significant events, such as a hospital admission, new diagnosis, change in renal function, move into residential aged care or the loss of a carer. Patients in remote areas may need telephone or video follow-up, coordination with Aboriginal Community Controlled Health Services or alignment with outreach clinics. For people in Sydney, Perth or Adelaide, the issue may instead be navigating numerous providers and ensuring every service works from the same current list.
Staff need a consistent workflow and training in shared decision-making, health literacy, trauma-informed care and escalation of mental health concerns. A short template can prompt the team to record medication purpose, patient priorities, unresolved risks, monitoring dates and communication completed. Audit a sample of records regularly, then adjust the process when it creates duplication or fails to reach patients.
The strongest programs make the safe choice the easy choice. They give patients a concise medicines list, a reliable contact point and clear instructions for changes. They give clinicians timely information and defined responsibilities. They also leave room for professional judgement, because a person with multiple chronic conditions cannot be managed safely by a checklist alone.
Start by selecting a small group of high-risk patients and completing a thorough medicines reconciliation. Invite the patient, GP, pharmacist and relevant care professionals to agree on priorities, monitoring and follow-up. Test the process, measure whether it reduces confusion and harm, and refine it before extending the service across the practice or pharmacy. A coordinated medication management program can turn fragmented treatment into care that is safer, clearer and genuinely aligned with the patient’s life.